| pubmed-article:15229762 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15229762 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:15229762 | lifeskim:mentions | umls-concept:C0155626 | lld:lifeskim |
| pubmed-article:15229762 | lifeskim:mentions | umls-concept:C0040223 | lld:lifeskim |
| pubmed-article:15229762 | lifeskim:mentions | umls-concept:C0006823 | lld:lifeskim |
| pubmed-article:15229762 | lifeskim:mentions | umls-concept:C0040044 | lld:lifeskim |
| pubmed-article:15229762 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:15229762 | pubmed:dateCreated | 2004-7-1 | lld:pubmed |
| pubmed-article:15229762 | pubmed:abstractText | Fibrinolytic therapy has become the standard therapy for acute myocardial infarction with ST segment elevation. Many clinical trials have established that early administration of therapy correlates with improved outcomes. However, there are very few published data analyzing time to treatment in Canadian hospitals. | lld:pubmed |
| pubmed-article:15229762 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15229762 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15229762 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15229762 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15229762 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15229762 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:15229762 | pubmed:issn | 0828-282X | lld:pubmed |
| pubmed-article:15229762 | pubmed:author | pubmed-author:CoxJafna LJL | lld:pubmed |
| pubmed-article:15229762 | pubmed:author | pubmed-author:HuynhThaoT | lld:pubmed |
| pubmed-article:15229762 | pubmed:author | pubmed-author:DalyPaul APA | lld:pubmed |
| pubmed-article:15229762 | pubmed:author | pubmed-author:ChristensonJa... | lld:pubmed |
| pubmed-article:15229762 | pubmed:author | pubmed-author:MathesonSandr... | lld:pubmed |
| pubmed-article:15229762 | pubmed:author | pubmed-author:HilbeJosephJ | lld:pubmed |
| pubmed-article:15229762 | pubmed:author | pubmed-author:DaviesCherylC | lld:pubmed |
| pubmed-article:15229762 | pubmed:author | pubmed-author:FASTRAK II... | lld:pubmed |
| pubmed-article:15229762 | pubmed:author | pubmed-author:CampbellAlana... | lld:pubmed |
| pubmed-article:15229762 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15229762 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:15229762 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15229762 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15229762 | pubmed:pagination | 801-5 | lld:pubmed |
| pubmed-article:15229762 | pubmed:dateRevised | 2008-4-9 | lld:pubmed |
| pubmed-article:15229762 | pubmed:meshHeading | pubmed-meshheading:15229762... | lld:pubmed |
| pubmed-article:15229762 | pubmed:meshHeading | pubmed-meshheading:15229762... | lld:pubmed |
| pubmed-article:15229762 | pubmed:meshHeading | pubmed-meshheading:15229762... | lld:pubmed |
| pubmed-article:15229762 | pubmed:meshHeading | pubmed-meshheading:15229762... | lld:pubmed |
| pubmed-article:15229762 | pubmed:meshHeading | pubmed-meshheading:15229762... | lld:pubmed |
| pubmed-article:15229762 | pubmed:meshHeading | pubmed-meshheading:15229762... | lld:pubmed |
| pubmed-article:15229762 | pubmed:meshHeading | pubmed-meshheading:15229762... | lld:pubmed |
| pubmed-article:15229762 | pubmed:meshHeading | pubmed-meshheading:15229762... | lld:pubmed |
| pubmed-article:15229762 | pubmed:meshHeading | pubmed-meshheading:15229762... | lld:pubmed |
| pubmed-article:15229762 | pubmed:meshHeading | pubmed-meshheading:15229762... | lld:pubmed |
| pubmed-article:15229762 | pubmed:meshHeading | pubmed-meshheading:15229762... | lld:pubmed |
| pubmed-article:15229762 | pubmed:meshHeading | pubmed-meshheading:15229762... | lld:pubmed |
| pubmed-article:15229762 | pubmed:meshHeading | pubmed-meshheading:15229762... | lld:pubmed |
| pubmed-article:15229762 | pubmed:meshHeading | pubmed-meshheading:15229762... | lld:pubmed |
| pubmed-article:15229762 | pubmed:meshHeading | pubmed-meshheading:15229762... | lld:pubmed |
| pubmed-article:15229762 | pubmed:meshHeading | pubmed-meshheading:15229762... | lld:pubmed |
| pubmed-article:15229762 | pubmed:meshHeading | pubmed-meshheading:15229762... | lld:pubmed |
| pubmed-article:15229762 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15229762 | pubmed:articleTitle | Fibrinolytic therapy in acute myocardial infarction: time to treatment in Canada. | lld:pubmed |
| pubmed-article:15229762 | pubmed:affiliation | Centre for Clinical Epidemiology and Evaluation, Vancouver General Hospital, British Columbia. cdavies@vanhosp.bc.ca | lld:pubmed |
| pubmed-article:15229762 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15229762 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:15229762 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15229762 | lld:pubmed |
